ALPEGA
14.3.2024 13:01:32 CET | Business Wire | Press release
Alpega, a leading global logistics SaaS software company, announces the appointment of Natasha Adams as its new Chief Marketing Officer (CMO). With over two decades of experience in driving growth and transformation across diverse industries, Natasha brings a wealth of expertise and a proven track record of success to Alpega.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314511062/en/
Natasha Adams, Alpega's new CMO (Photo: Alpega)
Known for her unwavering commitment to driving transformation, Natasha consistently embraces a business-first approach to achieve remarkable growth. With a breadth of experience spanning various sectors, including Supply Chain Tech, Oil and Gas, Deep Tech AI and Analytics, Martech, and even spearheading the development of a photography marketplace, Natasha's versatility and adaptability shine through in her ability to drive success across industries.
Throughout her extensive global career, Natasha has showcased exceptional proficiency in operational excellence, sales promotion, brand transformation, decision-making, and problem-solving.As CMO at Vortexa, she played a pivotal role in establishing the company as a category leader, achieving exponential double-digit revenue growth, and contributing to a successful Series C funding round. Furthermore, in her tenure as CMO of Transporeon, Natasha was instrumental in orchestrating the company's transformation into a global leader in Supply Chain Tech, culminating in a successful exit in 2023.
Todd DeLaughter, CEO of Alpega, added, "We are delighted to welcome Natasha to Alpega. Her extensive experience and proven track record in driving growth and transformation will be invaluable as we continue to innovate and expand our market presence. We look forward to her leadership in propelling Alpega to new heights."
Natasha stated, “I see Alpega as absolutely unique in the transportation logistics space as the only player in the market with solutions for shippers and carriers, supported by the largest open carrier network of any TMS vendor in the market”.
Natasha's appointment marks a significant milestone for Alpega Group as the company continues to strengthen its leadership team and drive forward its vision for growth and innovation in the transportation logistics space.
Alpega
Alpega is a a leading global logistics SaaS software company, dedicated to delivering end-to-end solutions that comprehensively address all transport requirements. Our mission is to empower shippers and carriers through efficient digitalization to meet today’s logistics challenges, driving smarter logistics for a greener tomorrow.
Drawing on extensive carrier-based assets, Alpega delivers tangible benefits across Execution, Planning, Sourcing and Payment solutions. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers, coupled with an 80,000-strong open carrier network covering around 10% of all commercial trucks in Europe, we are at the forefront of innovation and efficiency. For our carriers, our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of expertise in transportation, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and heightened visibility. Alpega's suite of solutions synergistically generates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, seamlessly connected electronically each day to efficiently manage vital transport operations. Operating in 80 countries globally, Alpega boasts a diverse team of over 600 professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314511062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom